Human coagulation factor VIII (FVⅢ) ELISA Kit

Code CSB-E13861h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
coagulation factor VIII, procoagulant component
Alternative Names
AHF ELISA Kit; Antihemophilic factor ELISA Kit; Coagulation factor VIII ELISA Kit; coagulation factor VIII; procoagulant component ELISA Kit; coagulation factor VIIIc ELISA Kit; DXS1253E ELISA Kit; F8 ELISA Kit; F8b ELISA Kit; F8c ELISA Kit; FA8_HUMAN ELISA Kit; factor VIII F8B ELISA Kit; Factor VIIIa light chain ELISA Kit; FactorVIII ELISA Kit; FVIII ELISA Kit; Hema ELISA Kit; Hemophilia A ELISA Kit; Hemophilia; classic ELISA Kit; OTTHUMP00000061446 ELISA Kit; OTTHUMP00000196174 ELISA Kit; Procoagulant component ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
12.5 ng/mL-800 ng/mL
3.12 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human FVIII antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled FVIII antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human Coagulation factor VIII (F8) ELISA Kit was designed for the quantitative measurement of Human Coagulation factor VIII (F8) protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 12.5 ng/mL-800 ng/mL and the sensitivity is 3.12 ng/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here


Would you please help us with some questions concerning sample preparation for the quantitative determination of human coagulation factor VIII (FVⅢ) concentrations using Factor VIII ELISA Kit (CSB-E13861h)?
1. Which is better to use plasma or serum?
2. In the case of plasma, which anticoagulant is better to use? May be it's better to use sodium citrate?
3. Is it possible to freeze the samples before analysis? At what temperature? Should we use shock freezing in liquid nitrogen followed by storage at -70℃?


Both serum and plasma can be detected with this kit. Of course, the matrix component of serum is relatively simple. For plasma, we mostly use EDTA as anticoagulation.
Samples are recommended to be tested as soon as possible. It can be stored at 4 degrees for a week, and at -80 ℃ for about 2 months. Avoid repeated freeze-thaw cycles.
If you are worried about it, pre-experiment is recommended to carry out first.

Target Background

(From Uniprot)
Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.
Gene References into Functions
  1. This study describes an original pathological mechanism by which a small intronic deletion in F8 leads to Alu exonization. PMID: 29357978
  2. A common polymorphism decreases LRP1 mRNA stability and is associated with increased plasma factor VIII levels PMID: 28431990
  3. F8 and F9 gene variants result from a founder effect in two large French haemophilia cohorts PMID: 29656491
  4. our results demonstrate that the N-glycosylation sequon in the A2 domain is located in a structural element that is critically required for proper folding and conformation of FVIII. PMID: 28327546
  5. The aim of this study was to determine the F8 mutations in severe HA (sHA) patients and female carriers PMID: 29938987
  6. Human FVIII gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD4(+) T cell mediated. PMID: 28799202
  7. In Factor VIII, 41 mutations were identified, 19 of which were novel and 80% (44/55) of the pathogenic mutations fell into the categories of missense, nonsense(16.36%), frameshift (14.55%), and splice (5.45%) mutations. PMID: 28252515
  8. High dose of rhFVIII induces apoptosis in FVIII-specific memory B-cells but does not influence FVIII-specific T cell response. PMID: 28492697
  9. the potential role of FXIII-A in wound healing, as a field with long-term therapeutic implications, is also discussed PMID: 28894750
  10. Case Report: complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis in proband's mother. PMID: 28492696
  11. Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease. PMID: 27734074
  12. Each hFVIII vector was administered to FVIII knockout (KO) mice at a dose of 10(10) genome copies (GC) per mouse. Criteria for distinguishing the performance of the different enhancer/promoter combinations were established prior to the initiation of the studies. PMID: 28056565
  13. Relevance of ethnic differences in factor XIII activity on laboratory reference ranges. PMID: 28488800
  14. analysis of co-existing variants in both F8 and PTGS-1 genes in a three-generation pedigree of hemophilia A PMID: 27629384
  15. Potential mutations of the F8 gene were analyzed. PMID: 28777843
  16. FVIII endocytosis is driven by interaction with LRP1 PMID: 28558995
  17. Of special importance is the sequential formation of disulfide bonds with different functions in structural support of VWF multimers, which are packaged, stored and further processed after secretion. Here, all these processes are being reviewed in detail including background information on the occurring biochemical reactions. [review] PMID: 28139814
  18. The FVIII C1 domain contributes significantly to the immune response against FVIII in acquired and congenital hemophilia inhibitor patients. PMID: 28507083
  19. the existing epidemiologic investigations with an overview of the range of possible biochemical and immunologic mechanisms that may contribute to the different immune outcomes observed with plasma-derived and recombinant FVIII products. PMID: 28432221
  20. discuss potential mechanisms through which these intronic SNPs regulate ST3GAL4 biosynthesis and the activity that affects VWF and FVIII PMID: 27584569
  21. the half-life of VWF ( approximately 15 hours) appears to be the limiting factor that has confounded attempts to extend the half-life of rFVIII. PMID: 27587878
  22. results revealed localized vascular expression of FVIII and von Willebrand factor and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues. PMID: 27207787
  23. NGS analysis has identified a large deletion of exon 2 of the F8 gene in a family affected with hemophilia A. PMID: 27984605
  24. the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor masks the reducing effect of mutations in the C domains on factor VIII immunogenicity. PMID: 27758819
  25. Galectin-1 and Galectin-3 are novel-binding partners for human FVIII. Gal-1 binding can influence the procoagulant activity of FVIII. PMID: 27013611
  26. In general, NGS provides an effective approach to screen for different HA causing mutation types in the F8 gene. PMID: 27824209
  27. Our results confirm the rare event of Haemophilia A and haemophilia B in the same patient originating from two distinct genetic defects in F8 and F9 genes. PMID: 27824213
  28. although fVIII bound avidly to soluble forms of clusters II and IV from LRP1, only soluble cluster IV competed with the binding of fVIII to full-length LRP1, revealing that cluster IV represents the major fVIII binding site in LRP1. PMID: 27794518
  29. The FVIII B domain variants, p.D963N, p.S806T, p.G873D, p.H998Q and p.Q1225R may be considered as polymorphism or non-pathologic mutations in patients with Haemophilia A. PMID: 26915717
  30. In this meta-analysis, we have assessed the association between the FXIII-A Val34Leu polymorphism and intracerebral hemorrhage risk. The results of a combined analysis showed no significant association between the FXIII-A Val34Leu polymorphism and ICH risk in the overall population. The results of this meta-analysis suggest that the FXIII-A Val34Leu polymorphism is not associated with ICH risk in a Caucasian population. PMID: 27525858
  31. this study shows that targeted high-throughput sequencing is an effective technique to detect the F8 gene mutations in hemophilia patients PMID: 27292088
  32. F8 intron 22 inversions and SNP rs73563631 have roles in severe hemophilia A in unrelated families PMID: 26489971
  33. von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII. PMID: 26635035
  34. Desmopressin acetate increases F8 plasma concentration in patients with combined deficiency of factors V and VIII. PMID: 26599105
  35. 37 (70%) of the 53 had discordant antigen-activity ratio, majority of those mutations produced FVIII with low FVIII-specific activity. However, 4 (7.5%) of the 53 mutations produced higher specific activity of FVIII. It is possible that these mutations either produce a secretory defect or an increased metabolic turnover to account for the low levels of FVIII with these mutations. PMID: 25550078
  36. In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific induced pluripotent stem cells has been described. PMID: 26743572
  37. Platelet-targeted FVIII gene therapy has higher therapeutic efficacy compared to factor VIII replacement therapy may be due to accelerated thrombin generation. PMID: 26453193
  38. Five int22h homologous copies at the Xq28 locus identified in intron22 inversion type 3 of the Factor VIII gene. PMID: 26653368
  39. Letter: report deep intronic variants of factor VII gene in hemophilia A. PMID: 26246214
  40. Carriers of Inv22 or Inv1 of F8 may be precisely detected with inverse-shifting PCR PMID: 27455009
  41. Factor VIII 3E6 antibody binding decreases the thermal motion behavior of surface loops in the C2 domain on the opposing face, thereby suggesting that cooperative antibody binding is a dynamic effect. PMID: 26598467
  42. 3030 SNPS, 31 Indels and a large, 497 kb, deletion were found among 2535 subjects from 26 different ethnic groups participating in the 1000 Genomes Project. PMID: 26383047
  43. Coagulation test results showed that the presence of double Glu113Asp, Arg593Cys mutations has a slightly synergistic effect on FVIII activity. PMID: 26057490
  44. Report a dose-response relationship between high FVIII levels and risk of death in venous thrombosis patients and in individuals from the general population. PMID: 26264493
  45. Case Report: P1809L mutation in A3 induced the conformational change in the FVIII molecule that hampered antigenic determinant(s) located in the C2 domain and might result in the inhibitor development. PMID: 26278069
  46. FVIII predicted venous thrombosis recurrence in a dose-response fashion, overall and in several subgroups, and is a strong candidate component of recurrence prediction tools. PMID: 26270389
  47. FXIII expression was upregulated in the airways of asthmatic patients after allergen exposure. PMID: 26525229
  48. Interaction between VWF and FVIII in treating VWD. PMID: 25605439
  49. large F8 rearrangements pose the highest risk, while missense mutations pose the lowest risk of inhibitor development in Indian hemophilia A patients PMID: 26897466
  50. Identify deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene. PMID: 25948085

Show More

Hide All

Involvement in disease
Hemophilia A (HEMA)
Subcellular Location
Secreted, extracellular space.
Protein Families
Multicopper oxidase family
Database Links

HGNC: 3546

OMIM: 134500

KEGG: hsa:2157

STRING: 9606.ENSP00000353393

UniGene: Hs.632836

CUSABIO guaranteed quality
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1